Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report

There are limited data on the clinical efficiency of afatinib in non‐small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we desc...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2020-02, Vol.11 (2), p.447-450
Main Authors: Iida, Yuko, Kumasawa, Fumio, Shimizu, Tetsuo, Shintani, Yoshitaka, Takahashi, Noriaki, Gon, Yasuhiro
Format: Article
Language:English
Subjects:
Afatinib
Afatinib - therapeutic use
Aged, 80 and over
Antigens
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Case Report
Case Reports
Diarrhea
Epidermal growth factor
ErbB Receptors - genetics
Female
Humans
L861Q
low‐dose
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Metastasis
Mutation
non‐small cell lung cancer
Patients
Prognosis
Remission Induction
Skin
uncommon epidermal growth factor receptor mutation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are limited data on the clinical efficiency of afatinib in non‐small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we describe a case of successful treatment of a patient aged >80 years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low‐dose afatinib. An 83‐year‐old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusion, and multiple lung metastases in both lungs. The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. The patient received 30 mg/day of afatinib and experienced no severe adverse events. Two weeks later, partial response was observed based on a CT scan. The results of the present case support the effectiveness and safety of low‐dose afatinib in elderly patients with EGFR L861Q mutation‐positive NSCLC.
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.13269